Custom Search
Showing posts with label SWOT OF INDIAN PHARMACEUTICAL INDUSTRIES. Show all posts
Showing posts with label SWOT OF INDIAN PHARMACEUTICAL INDUSTRIES. Show all posts

SWOT OF INDIAN PHARMACEUTICAL INDUSTRIES

Swot of Indian pharmaceutical industry

Strengths

  • Cost competitiveness
  • Well developed industry with strong manufacturing base
  • Well established network of laboratories and r&d infrastructure, strong motivated scientific force
  • Self reliant technology for production
  • Access to pool of highly trained scientists
  • Strong marketing and distribution network
  • Rich biodiversity
  • Low r&d costs
  • Competencies in chemistry and process development
  • Cost effective technologies for bulk drugs production and well developed capital equipment industry
  • Increasingly, india is being regarded as a manufacturing base by global pharmaceutical companies.

Weakness

  • Low investments in innovative r&d.
  • Lack of resources to compete with mncs for new drug discovery research and to commercialize molecules on a worldwide basis.
  • Lack of strong linkages between industry and academia.
  • Lack of culture of innovation in the industry
  • Low medical expenditure and healthcare spend in the country
  • Inadequate regulatory standards
  • Production of spurious and low quality drugs tarnishes the image of industry at home and abroad.

Opportunities

  • Significant export potential
  • Licensing deals with mncs for ndds
  • Marketing alliances to sell mnc products in domestic market
  • Contract manufacturing arrangements with mncs
  • Potential for developing india as a centre for international clinical trials
  • Niche player in global pharmaceutical r&d.
  • Strong base of scientific as well as technical manpower and also due to pioneering work done in process development
  • Supply of generic drugs to developed markets

Threats

  • Product patent regime poses serious challenge to domestic industry unless it invests in research and development.
  • Dpco puts unrealistic ceilings on product prices and profitability and prevents pharmaceutical companies from generating investible surplus
  • R&d efforts of indian pharmaceutical companies hampered by lack of enabling regulatory requirement.
  • Entrants of newer players in highly fragmented market.

Custom Search